Sugi Predict

Sugi Predict / Compounds / SCHEMBL5889451

SCHEMBL5889451

SCHEMBL5889451

N#CCCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CA2 P00918 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ GLS O94925 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29459491 1.00 MAPT (0.60) MAPTALDH1A1CA2CA9TDP1
SCHEMBL5840903 0.95 TDP1 (0.56) MAPTALDH1A1CA2CA9TDP1
SCHEMBL10061543 0.93 TDP1 (0.58) MAPTALDH1A1TDP1L3MBTL1CYP1A2
SCHEMBL8688325 0.93 TDP1 (0.58) MAPTALDH1A1TDP1L3MBTL1CYP1A2
SCHEMBL6993290 0.89 DRD3 (0.55) MAPTALDH1A1CA2CA9TDP1
SCHEMBL29459546 0.89 DRD3 (0.55) MAPTALDH1A1CA2CA9TDP1
SCHEMBL25030174 0.85 MAPT (0.50) MAPTALDH1A1TDP1L3MBTL1RAB9A
SCHEMBL30233911 0.85 MAPT (0.50) MAPTALDH1A1TDP1L3MBTL1RAB9A
SCHEMBL7347496 0.83 TDP1 (0.54) MAPTTDP1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL5801403 0.82 NPC1 (0.50) MAPTALDH1A1CA2CA9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113527130-B Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound 兰州大学 2023-07-18 — — CN claimed
CN-113527130-A Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound 兰州大学 2021-10-22 — — CN claimed
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof LUPIN LIMITED (IN) 2025-11-25 — — US disclosed
US-20250057958-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-02-20 — — US disclosed
EP-4004002-B1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF LUPIN LTD (IN) 2024-07-10 — — EP disclosed
EP-4004002-B1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF LUPIN LTD (IN) 2024-07-10 — — EP disclosed
CN-114174303-B Macrocyclic compounds as STING agonists and methods and uses thereof 印度鲁宾有限公司 2024-06-25 — — CN disclosed
WO-2023161881-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 — — WO disclosed
CN-113527130-B Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound 兰州大学 2023-07-18 — — CN disclosed
US-20220289763-A1 Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof LUPIN LIMITED (IN) 2022-09-15 — — US disclosed
EP-4004002-A1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF Lupin Limited (IN) 2022-06-01 — — EP disclosed
WO-2002000650-A2 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2002-01-03 — — WO disclosed
US-20010049453-A1 Process for producing salts of cyanobenzylamines SHOWA DENKO K.K. 2001-12-06 — — US disclosed
EP-1151989-A1 PROCESS FOR PRODUCING SALT OF CYANOBENZYLAMINE OR DERIVATIVE Showa Denko K.K. (JP) 2001-11-07 — — EP disclosed
EP-1097920-A1 Intermediate for condensed benzazepine derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2001-05-09 — — EP disclosed
US-5834499-A TREATING GASTROINTESTINAL DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-11-10 — — US disclosed
US-5723606-A Condensed benzazepine derivative and pharmaceutical composition thereof YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-03-03 — — US disclosed
CN-1143364-A 5-HT3 receptor agonist, novel thiazole derivative, and intermediate thereof YAMANOUCHI PHARMA CO LTD (JP) 1997-02-19 — — CN disclosed
EP-0749966-A1 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-12-27 — — EP disclosed
EP-0110754-A1 Process for the synthesis of 4-aminobutyramide-hydrochloride DESHORS (FR) 1984-06-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof STING1, CGAS, MAVS MAPT 2326/4885ALDH1A1 4861/4885CA2 2314/4885
US-20250057958-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 MAPT 4594/4885ALDH1A1 4466/4885CA2 3745/4885
US-20010049453-A1 Process for producing salts of cyanobenzylamines MMAB, BLVRB, SLC6A12 MAPT 2222/4885ALDH1A1 2927/4885CA2 321/4885
US-20220289763-A1 Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof STING1, CGAS, MAVS MAPT 2326/4885ALDH1A1 4861/4885CA2 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.